IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 306 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,733 | +42.6% | 699,553 | +29.0% | 0.02% | +42.9% |
| Q2 2023 | $22,247 | +35.7% | 542,232 | +18.2% | 0.01% | +75.0% |
| Q1 2023 | $16,397 | -14.4% | 458,817 | -9.6% | 0.01% | -11.1% |
| Q4 2022 | $19,162 | -99.9% | 507,311 | +0.6% | 0.01% | -62.5% |
| Q3 2022 | $22,313,000 | +70.0% | 504,488 | +42.3% | 0.02% | +200.0% |
| Q2 2022 | $13,127,000 | +12.0% | 354,579 | +12.1% | 0.01% | -11.1% |
| Q1 2022 | $11,717,000 | -41.6% | 316,350 | -52.1% | 0.01% | +125.0% |
| Q4 2021 | $20,078,000 | +81.2% | 659,876 | +99.8% | 0.00% | -20.0% |
| Q3 2021 | $11,079,000 | -23.7% | 330,291 | -9.3% | 0.01% | -28.6% |
| Q2 2021 | $14,520,000 | +226.9% | 363,996 | +268.5% | 0.01% | +250.0% |
| Q1 2021 | $4,442,000 | -33.6% | 98,771 | -16.5% | 0.00% | -33.3% |
| Q4 2020 | $6,687,000 | +13.2% | 118,265 | -5.0% | 0.00% | 0.0% |
| Q3 2020 | $5,905,000 | -25.3% | 124,447 | -7.1% | 0.00% | -50.0% |
| Q2 2020 | $7,900,000 | +17.2% | 134,001 | -6.0% | 0.01% | +20.0% |
| Q1 2020 | $6,743,000 | -60.6% | 142,622 | -49.6% | 0.01% | -44.4% |
| Q4 2019 | $17,107,000 | +32.8% | 283,180 | +31.7% | 0.01% | +12.5% |
| Q3 2019 | $12,884,000 | -41.8% | 215,059 | -37.6% | 0.01% | -38.5% |
| Q2 2019 | $22,142,000 | +4.7% | 344,493 | +32.2% | 0.01% | -13.3% |
| Q1 2019 | $21,145,000 | +38.4% | 260,508 | -7.8% | 0.02% | +15.4% |
| Q4 2018 | $15,279,000 | -17.2% | 282,657 | -21.0% | 0.01% | 0.0% |
| Q3 2018 | $18,452,000 | +91.5% | 357,736 | +54.8% | 0.01% | +85.7% |
| Q2 2018 | $9,633,000 | -30.9% | 231,155 | -26.9% | 0.01% | -36.4% |
| Q1 2018 | $13,942,000 | -23.3% | 316,345 | -12.4% | 0.01% | -31.2% |
| Q4 2017 | $18,166,000 | +0.2% | 361,168 | +1.0% | 0.02% | -15.8% |
| Q3 2017 | $18,126,000 | +31.8% | 357,507 | +32.3% | 0.02% | +26.7% |
| Q2 2017 | $13,748,000 | -8.4% | 270,251 | -27.6% | 0.02% | -6.2% |
| Q1 2017 | $15,008,000 | +25.7% | 373,290 | +49.5% | 0.02% | +33.3% |
| Q4 2016 | $11,944,000 | -8.8% | 249,728 | -30.1% | 0.01% | -14.3% |
| Q3 2016 | $13,092,000 | +152.6% | 357,351 | +60.6% | 0.01% | +133.3% |
| Q2 2016 | $5,182,000 | -21.0% | 222,466 | +35.7% | 0.01% | -40.0% |
| Q1 2016 | $6,557,000 | -42.8% | 163,936 | -12.7% | 0.01% | -28.6% |
| Q4 2015 | $11,457,000 | – | 187,795 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |